Welcome to the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2) home page. SCORE2 is a multi-center, prospective, randomized non-inferiority trial of eyes with macular edema secondary to central retinal vein occlusion, comparing intravitreal bevacizumab every 4 weeks with intravitreal aflibercept every 4 weeks. Participants meeting eligibility criterion will be followed on study drug for 12 months. Participants who complete 12 months on drug, will continue being observed annually for up to 5 years. Approximately 80 clinical sites throughout the United States will participate in SCORE2. For more information about SCORE2 go to clinicaltrials.gov.

SCORE2 is sponsored by the National Eye Institute, National Institutes of Health, Department of Health and Human Services in Bethesda, Maryland.